Agios Announces Clinical and Preclinical Data to be Presented at AACR Annual Meeting 2014
Agios will host a live event with a webcast on Sunday, April 6, 2014, at
The schedule for Agios’ oral presentations and poster sessions is as follows:
Clinical Presentation
Date & Time:
Session
Title: Novel Immune and Targeted Therapies for Hematologic Malignancies
and Solid Tumors
Session Type: Clinical Trials Symposium
Presentation
Title: Clinical safety and activity in a phase I trial of AG-221, a
first in class, potent inhibitor of the IDH2-mutant protein, in patients
with IDH2 mutant positive advanced hematologic malignancies
Presenter:
Location:
Ballroom 20A-C,
Preclinical Poster and Oral Presentations
Date & Time:
Session
Title: IDH Mutations in Cancer
Session Type: Major Symposium
Presentation
Title: Development of mutant IDH2 inhibitors: from concept to patients
Presenter:
Location:
Ballroom 20 A-C,
Date & Time:
Session
Title: Cancer Metabolism: New Pathways and Progress Toward Therapy
Session
Type: Minisymposium
Presentation Title: IDH2 (R140Q) knock-in mouse
recapitulating human type II D-2-hydroxyglutaric aciduria
Presenter:
Fang Wang, Ph.D., associate director,
Location:
Room 6CF,
Date & Time:
Session
Title: Human to Mouse 1
Session Type: Poster Session
Presentation
Title: IDH1 mutant inhibitor induces cellular differentiation and offers
a combination benefit with Ara-C in a primary human IDH1 mutant AML
xenograft model
Presenter:
Location: Hall A-E, Poster Section 8,
Date and Time:
Session
Title: Epigenetics 3: DNA Methylation
Session Type: Poster Session
Presentation
Title: IDH2 mutation induced histone and DNA hypermethylation is
progressively reversed by small molecule inhibition
Presenter:
Location:
Hall A-E, Poster Section 18,
Date & Time:
Session
Title: Preclinical Studies in Model Organisms
Session Type: Poster
Session
Presentation Title: AG-221 offers a survival advantage in a
primary human IDH2 mutant AML xenograft model
Presenter:
Location: Hall
A-E, Poster Section 7,
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include those regarding Agios’ expectations
and beliefs about the potential of its cancer metabolism programs and
the benefit of its strategic plans and focus. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “would” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual events
or results to differ materially from Agios’ current expectations and
beliefs. For example, there can be no guarantee that any product
candidate Agios is developing will successfully commence or complete
necessary preclinical and clinical development phases, or that
development of any of Agios’ product candidates will successfully
continue. There can be no guarantee that any positive developments in
Agios’ business will result in stock price appreciation. Management’s
expectations and, therefore, any forward-looking statements in this
press release could also be affected by risks and uncertainties relating
to a number of other important factors, including: Agios’ results of
clinical trials and preclinical studies, including subsequent analysis
of existing data and new data received from ongoing and future studies;
the content and timing of decisions made by the U.S.
Source:
Agios Pharmaceuticals:
Glenn Goddard, SVP Finance
investors@agios.com
or
Media
Contact:
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com
